Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CSCPDPC- CDMC) (U01)
The summary for the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CSCPDPC- CDMC) (U01) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CSCPDPC- CDMC) (U01): This Funding Opportunity Announcement (FOA) invites U01 applications for the establishment of a clinical consortium, composed of one Coordination and Data Management Center (CDMC) and up to 9 Clinical Centers (CC), to conduct studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes.
The Consortium will form multi-disciplinary teams composed of members from the CCs and CDMC to undertake a comprehensive clinical, epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The teams will also undertake studies on the development of pancreatic cancer in newly diagnosed diabetic patients.
Applications for the consortium Clinical Centers are being solicited via RFA-DK-14-027 "Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC-CCs) (U01)".
To achieve the goal of a comprehensive characterization of evolving chronic pancreatitis and pancreatic cancer, the Coordinating and Data Management Center (CDMC) will take on the administrative and data collection/analysis functions and will be responsible for the conduct of all of the ongoing and future studies of the CCs.
In addition, a major collaborative effort within the Consortium will be the establishment of an annotated repository of bio-specimens (blood, pancreatic and duodenal juice, stools and when feasible pancreatic tissue) to allow for the identification and validation of biomarkers for risk stratification and/or early detection.
The Consortium will form multi-disciplinary teams composed of members from the CCs and CDMC to undertake a comprehensive clinical, epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The teams will also undertake studies on the development of pancreatic cancer in newly diagnosed diabetic patients.
Applications for the consortium Clinical Centers are being solicited via RFA-DK-14-027 "Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC-CCs) (U01)".
To achieve the goal of a comprehensive characterization of evolving chronic pancreatitis and pancreatic cancer, the Coordinating and Data Management Center (CDMC) will take on the administrative and data collection/analysis functions and will be responsible for the conduct of all of the ongoing and future studies of the CCs.
In addition, a major collaborative effort within the Consortium will be the establishment of an annotated repository of bio-specimens (blood, pancreatic and duodenal juice, stools and when feasible pancreatic tissue) to allow for the identification and validation of biomarkers for risk stratification and/or early detection.
Federal Grant Title: | Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CSCPDPC- CDMC) (U01) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Education Food and Nutrition Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-DK-14-028 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.393, 93.399, 93.847 |
CFDA Descriptions: | Cancer Cause and Prevention Research; Cancer Control; Diabetes, Digestive, and Kidney Diseases Extramural Research |
Current Application Deadline: | Apr 2, 2015 |
Original Application Deadline: | Apr 2, 2015 |
Posted Date: | October 17th, 2014 |
Creation Date: | Oct 17, 2014 |
Archive Date: | May 3, 2015 |
Total Program Funding: | $6,000,000 |
Maximum Federal Grant Award: | $1,000,000 |
Minimum Federal Grant Award: | none |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- County governments
Public housing authorities/Indian housing authorities
Small businesses
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
Native American tribal organizations (other than Federally recognized tribal governments)
Others (see text field entitled "Additional Information on Eligibility" for clarification)
City or township governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
For profit organizations other than small businesses
Private institutions of higher education
Special district governments
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized) - Additional Information on Eligibility
- Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-028.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
National Institutes of Health 301-496-3405 - Similar Government Grants
- • Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
- • Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
- • National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer ...
- • Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...
- • Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...
- • Pilot Studies in Pancreatic Cancer
- • Cancer Prevention Research Small Grant Program
- • Molecular Targets for Nutrients in Prostate Cancer Prevention
- More Grants from the National Institutes of Health
- • Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required)
- • Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
- • Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clin...
- • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
- • Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data...